The pharmaceutical company Pfizer, sales rose 11 percent in the second quarter. Stock Photography.
-
- Mark Lennihan
‘); window.Fusion.initAd ( “mob_300x60_artikeltrue” “mob_300x60_artikel” pmFusionAsync); }} ‘); window.Fusion.initAd ( “ad_175x100_1_1true” “ad_175x100_1″ pmFusionAsync); }}
‘); window.Fusion.initAd ( “ad_175x100_1_2true” “ad_175x100_1″ pmFusionAsync); }}
the launch of a new drug for the treatment of breast cancer helped give Pfizer an extra boost in the second quarter. The US pharmaceutical giant reported a higher turnover than expected for the period. Sales rose 11 percent to 13.2 billion dollars, or 113 billion during the period, compared with $ 11.9 billion a year ago.
Analysts had on average expected a turnover of 13, 0 billion, according to a Reuters poll.
Net revenue declined to $ 2.0 billion, or 17 billion, compared with $ 2.6 billion last year.
in April scrapped Pfizer plans to buy the Irish botox maker Allergan for 160 billion dollars, about 1370 billion. A business that was about that Pfizer wanted to move its headquarters to Ireland to bring down the corporate tax rate.
No comments:
Post a Comment